Verrica Pharmaceuticals Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Verrica Pharmaceuticals Inc. stock issued during period, value, new issues for the quarter ending 2022-09-30 was $26.90M.
- Verrica Pharmaceuticals Inc. stock issued during period, value, new issues for the quarter ending 2021-03-31 was $28.11M.
- Verrica Pharmaceuticals Inc. stock issued during period, value, new issues for the quarter ending 2018-12-31 was $2.00K.
- Verrica Pharmaceuticals Inc. stock issued during period, value, new issues for the quarter ending 2018-09-30 was -$7.00K.
- Verrica Pharmaceuticals Inc. stock issued during period, value, new issues for fiscal 2025 was $49.12M, a 23.92% increase from fiscal 2024.
- Verrica Pharmaceuticals Inc. stock issued during period, value, new issues for fiscal 2024 was $39.64M, a 30.81% increase from fiscal 2023.
- Verrica Pharmaceuticals Inc. stock issued during period, value, new issues for fiscal 2023 was $30.30M, a 12.64% increase from fiscal 2022.
- Verrica Pharmaceuticals Inc. stock issued during period, value, new issues for fiscal 2022 was $26.90M, a 4.33% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2025-12-31 | $49.12M 10-K · filed 2026-03-11 | |
| 2024-12-31 | $39.64M 10-K · filed 2026-03-11 | |
| 2023-12-31 | $30.30M 10-K · filed 2025-03-11 | |
| 2022-12-31 | $26.90M 10-K · filed 2024-02-29 | |
| 2022-09-30 | $26.90M 10-Q · filed 2023-11-09 | |
| 2021-12-31 | $28.12M 10-K · filed 2023-03-06 | |
| 2021-03-31 | $28.11M 10-Q · filed 2022-11-07 | |
| 2018-12-31 | $2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-13 | $78.38M 10-K · filed 2020-03-13 |
| 2018-09-30 | -$7.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | |
| 2018-06-30 | $78.38M 10-Q · filed 2019-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |